Figures & data
Figure 1. Attrition algorithm for patients with (a) mHSPC and (b) nmCRPC. *Patients identified by definition A and definition B were not mutually exclusive. Abbreviations. mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC, prostate cancer; PSA, prostate-specific antigen.
![Figure 1. Attrition algorithm for patients with (a) mHSPC and (b) nmCRPC. *Patients identified by definition A and definition B were not mutually exclusive. Abbreviations. mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC, prostate cancer; PSA, prostate-specific antigen.](/cms/asset/ff6cd51b-c4a3-41dd-940b-1934fa0f9891/ijme_a_2320001_f0001_b.jpg)
Figure 2. Prevalence and incidence of patients with (a) mHSPC and (b) nmCRPC over the study period. Abbreviations. mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer.
![Figure 2. Prevalence and incidence of patients with (a) mHSPC and (b) nmCRPC over the study period. Abbreviations. mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer.](/cms/asset/0c016d47-c1f3-4ee6-a2e5-5a8a427c80bc/ijme_a_2320001_f0002_c.jpg)
Table 1. Baseline demographic and clinical characteristics.
Figure 3. Medication use at baseline. ADT included LHRH agonist (leuprolide/Leuplin/leuprorelin, goserelin/Zoladex, triptorelin, and histrelin) and LHRH antagonist (degarelix/Gonax). Antiandrogens included bicalutamide and flutamide. Novel hormone therapy included enzalutamide and apalutamide. Abbreviations. ADT, androgen-deprivation therapy; LHRH luteinizing hormone-releasing hormone; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC prostate cancer.
![Figure 3. Medication use at baseline. ADT included LHRH agonist (leuprolide/Leuplin/leuprorelin, goserelin/Zoladex, triptorelin, and histrelin) and LHRH antagonist (degarelix/Gonax). Antiandrogens included bicalutamide and flutamide. Novel hormone therapy included enzalutamide and apalutamide. Abbreviations. ADT, androgen-deprivation therapy; LHRH luteinizing hormone-releasing hormone; mHSPC, metastatic hormone-sensitive prostate cancer; nmCRPC, nonmetastatic castration-resistant prostate cancer; PC prostate cancer.](/cms/asset/ff3f1326-20cc-427f-b9ba-6abcdf84eaf6/ijme_a_2320001_f0003_c.jpg)
Figure 4. Sankey diagram detailing changes of first line to second line of treatment in patients with mHSPC. Abbreviations. ADT, androgen-deprivation therapy; mHSPC, metastatic hormone-sensitive prostate cancer.
![Figure 4. Sankey diagram detailing changes of first line to second line of treatment in patients with mHSPC. Abbreviations. ADT, androgen-deprivation therapy; mHSPC, metastatic hormone-sensitive prostate cancer.](/cms/asset/85e077d8-b9c0-4715-871e-f3254fefd3c9/ijme_a_2320001_f0004_c.jpg)
Table 2. Potentially prostate cancer–related HRU for patients with mHSPC and nmCRPC.
Table 3. Potentially prostate cancer–related healthcare-associated costs for patients with mHSPC and nmCRPC.
Supplemental Material
Download MS Word (199.4 KB)Supplemental Material
Download EPS Image (1.7 MB)Data availability statement
The datasets used during this study are not publicly available due to local data access policy but may become available from the corresponding author upon reasonable request.